enVVeno Medical Corp
NASDAQ:NVNO
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Info Edge (India) Ltd
NSE:NAUKRI
|
IN |
enVVeno Medical Corp
Accrued Liabilities
enVVeno Medical Corp
Accrued Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accrued Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
enVVeno Medical Corp
NASDAQ:NVNO
|
Accrued Liabilities
$1.8m
|
CAGR 3-Years
26%
|
CAGR 5-Years
4%
|
CAGR 10-Years
N/A
|
|
|
Boston Scientific Corp
NYSE:BSX
|
Accrued Liabilities
$3.2B
|
CAGR 3-Years
18%
|
CAGR 5-Years
13%
|
CAGR 10-Years
10%
|
|
|
Edwards Lifesciences Corp
NYSE:EW
|
Accrued Liabilities
$1B
|
CAGR 3-Years
15%
|
CAGR 5-Years
12%
|
CAGR 10-Years
10%
|
|
|
Stryker Corp
NYSE:SYK
|
Accrued Liabilities
$4.2B
|
CAGR 3-Years
11%
|
CAGR 5-Years
7%
|
CAGR 10-Years
8%
|
|
|
Abbott Laboratories
NYSE:ABT
|
Accrued Liabilities
$7.6B
|
CAGR 3-Years
3%
|
CAGR 5-Years
3%
|
CAGR 10-Years
8%
|
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Accrued Liabilities
$1.1B
|
CAGR 3-Years
13%
|
CAGR 5-Years
18%
|
CAGR 10-Years
18%
|
|
enVVeno Medical Corp
Glance View
enVVeno Medical Corp. is a development stage medical device company, which develops tissue based solutions that are designed to be life sustaining or life enhancing for patients with cardiovascular disease, and peripheral arterial and venous disease. The company is headquartered in Irvine, California and currently employs 24 full-time employees. The company went IPO on 2018-05-31. The firm is focused on improving the standard of care in the treatment of venous disease. The firm is focused on developing tissue-based solutions that are designed for patients with chronic venous insufficiency (CVI). Its lead product, VenoValve, is a porcine based device being developed to surgically implanted in the deep venous system of the leg to treat severe CVI, including the potential to heal recurring venous leg ulcers. The VenoValve is designed to be implanted into the femoral vein of the patient in an open surgical procedure via a five-to-six-inch incision in the upper thigh. The VenoValve is being evaluated in the surgical anti-reflux venous valve endoprosthesis (SAVVE) United States clinical trial. In addition to the VenoValve, the Company is focused on the development of a second device, enVVe, for the treatment of venous disease.
See Also
What is enVVeno Medical Corp's Accrued Liabilities?
Accrued Liabilities
1.8m
USD
Based on the financial report for Dec 31, 2025, enVVeno Medical Corp's Accrued Liabilities amounts to 1.8m USD.
What is enVVeno Medical Corp's Accrued Liabilities growth rate?
Accrued Liabilities CAGR 5Y
4%
Over the last year, the Accrued Liabilities growth was 62%. The average annual Accrued Liabilities growth rates for enVVeno Medical Corp have been 26% over the past three years , 4% over the past five years .
